TaiGen Biopharmaceuticals Holdings Company Description

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide.

The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections.

It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C.

The company was founded in 2001 and is based in Taipei City, Taiwan.

TaiGen Biopharmaceuticals Holdings Limited

Country	Cayman Islands
Founded	2001
Industry	Biotechnology
Sector	Healthcare
CEO	Kuo-Lung Huang

Contact Details

Address: No. 138, Xinming Road Taipei, 11470 Taiwan
Phone	886 2 8177 7020
Website	taigenbiotech.com.tw

Stock Details

Ticker Symbol	4157
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	KYG866171005
SIC Code	2836

Key Executives

Name	Position
Kuo-Lung Huang	Chairman of the Board, Chief Executive Officer, President and Chief Commercial Officer in Asia
Dr. Ming-Chu Hsu Ph.D.	Founder
Richard Lu	Vice President of Finance
Mark Kao	Head of the Accounting Department
Dr. Peter W. Tsao M.B.A., Ph.D.	Vice President Corporate Development